Clinical Trial: Study of HXN6005 in Healthy Participants and Patients With Moderate-to-Severe Atopic Dermatitis

U.S., Aug. 25 -- ClinicalTrials.gov registry received information related to the study (NCT07782476) titled 'Study of HXN6005 in Healthy Participants and Patients With Moderate-to-Severe Atopic Dermatitis' on Aug. 13.

Brief Summary: This is a Phase I/II, multicenter, randomized, double-blind, placebo-controlled study evaluating HXN6005 in healthy participants and patients with moderate-to-severe atopic dermatitis (AD).

The study consists of three parts: Part A (single ascending dose in healthy participants), Part B (multiple ascending dose in AD patients), and Part C (multiple-dose efficacy and safety assessment in AD patients).

The primary objectives are to assess the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), a...